Terming the achievement as a "true success story of Atmanirbharta", he said that it was a unified effort of the government, vaccine manufac...

COVAXIN, the company's home-grown COVID-19 vaccine approved for emergency use in India, is one of two shots driving the country's massive v...

CEPI first partnered with IVI and Bharat Biotech in June 2020, providing up to USD 14.1 million for vaccine manufacturing and clinical deve...

Dr. Mariangela Simao, a WHO assistant director-general for vaccines, says the UN health agency’s assessment of the Bharat Biotech vaccine w...

Bharat Biotech's pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation (WHO)'s Emergency Use...

“For Covaxin, we will see a significant (production) ramp-up of more than double in August-September, when the doses manufactured by Bharat...

However, the report made it clear that efficacy cannot be determined by phase 2 trials and this required further corroboration with phase 3...

The trials involved 25,800 participants and was conducted in partnership with the Indian government's medical research body.

The endorsement letter from 49 medical experts, led by AIIMS’ former director TD Dogra, comes after reports emerged that some healthcare wo...

The Brazilian Ambassador to India Andr Aranha Corra do Lago expressed keen interest on behalf of his government towards procuring the vacci...

Bharat Biotech, which has developed India’s indigenous Covid-19 vaccine, Covaxin, has sought regulatory approval to start phase-1 and phase...

Bharat Biotech CEO Krishna Ella said he doesn’t know what the regulator meant when it accorded “emergency use permission under clinical tri...

The government officials said India’s vaccination drive is likely to begin in the next one to two weeks. The government plans to vaccinate ...

COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Resea...

The company statement has come after an expert panel of India's central drug authority recommended granting permission for restricted use o...

"COVAXIN clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the s...

The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce...